-
Heavy document released, Chinese medicine enterprises "going out" and speeding up
Time of Update: 2022-04-15
Vigorously develop TCM service trade and build a high-quality national TCM service export base; promote the overseas localization of TCM, promote industrial collaboration and international trade; encourage the development of "Internet + TCM trade"; gradually improve the "going out" of TCM Relevant measures, carry out policy research on the overseas market of traditional Chinese medicine, and help traditional Chinese medicine enterprises to "go global" .
-
After the second IPO, the pharmaceutical company finally landed on the GEM today!
Time of Update: 2022-04-15
According to public information, Fujilai is mainly engaged in the research and development, production and sales of pharmaceutical intermediates, APIs and raw materials for health care products.
-
A large number of pharmaceutical companies have intensively disclosed operating data from January to February, focusing on CXO, traditional Chinese medicine and other fields
Time of Update: 2022-04-15
A number of pharmaceutical companies have performed well and are expected to achieve rapid growth in performance from January to February, including WuXi AppTec, Huitai Medical, Zuoli Pharmaceutical, and Bloomage Bio .
-
The heavyweight domestic PD-1 listing application was accepted by the EMA, accelerating the process of globalization
Time of Update: 2022-04-15
[Pharmaceutical Industry News] Following the official acceptance of the new drug marketing application (BLA) of BeiGene's PD-1 monoclonal antibody Baizean by the US FDA in September 2021, the product has recently received a marketing authorization application and was approved by the European Medicines Agency The good news accepted by (EMA) means that Baizean is accelerating the process of globalization .
-
The prevalence of diabetes continues to rise, and traditional Chinese medicine is included in the national diabetes prevention and control guidelines
Time of Update: 2022-04-15
For the first time, the "Guidelines" added the "Traditional Chinese Medicine Prevention and Treatment of Diabetes" chapter to actively support and encourage the integration of traditional Chinese medicine into diabetes comprehensive The prevention and treatment system should give full play to the advantages of holistic view and syndrome differentiation, combined with physical constitution identification, etc.
-
CXO continues to develop well, and the performance of leading companies has risen sharply
Time of Update: 2022-04-15
[Pharmaceutical Network Industry News] In recent years, with the continuous transfer of global innovative drug outsourcing services to emerging Asian markets such as China, and the continuous complexity and refinement of the industrial chain of new drug R&D and production, the cost and the difficulty of R&D have increased.
By 2025, the market for new drug R&D outsourcing services may reach $244 billion .
-
More than 5,000 drugs have been reduced in price!
Time of Update: 2022-04-15
[Pharmaceutical Network Industry News] According to the 2021 Annual Monitoring Circular of the Provincial Pharmaceutical Recruitment and Procurement Price Guidance Mechanism issued by the Hainan Provincial Medical Insurance Bureau on March 17, 5,049 varieties of drugs were received by enterprises to reduce their prices, with an average decrease of 31.
-
The research and development of ALK inhibitors is booming, and domestic and foreign pharmaceutical companies such as Takeda and Betta Pharmaceuticals have deployed
Time of Update: 2022-04-15
Among them, crizotinib launched by Pfizer is the first ALK tyrosine kinase inhibitor launched in the world, bringing a new treatment option for ALK-positive advanced non-small cell lung cancer .
-
Technology is advancing rapidly, and the pharmaceutical industry is pushing for intelligent transformation
Time of Update: 2022-04-15
According to reports, in 2021, at the same time as the secondary research and development of varieties, Benxi Sanyao will invest 40 million yuan to carry out intelligent transformation in the production field .
-
Over 1 billion anti-epileptic drug varieties, usher in another over-reviewed pharmaceutical company!
Time of Update: 2022-04-15
com, in 2019, the terminal sales of sodium valproate in China's public medical institutions exceeded 2 billion yuan, and injections accounted for more than 60% of the market share .
-
There are nearly 5,000 varieties of traditional Chinese medicine formula granules registered in the country, and these pharmaceutical companies have more than 100
Time of Update: 2022-04-15
Among them, a number of manufacturers have more than 100 registered varieties, including China Traditional Chinese Medicine, Tianjin Hongri, Hunan Xinhui, China Resources Sanjiu, Sichuan New Green, etc.
Judging from the number of varieties of traditional Chinese medicine formula granules filed, both companies have more than 200, 302 and 219 respectively .
-
Pharmaceutical companies are scrambling to develop Class 1 new drugs, and new progress continues!
Time of Update: 2022-04-15
Luye Pharma's Class 1 New Drug Under Development Approved for Phase III Clinical Trials Recently, Luye Pharma announced that the group's new product under development (NCE) and China's Class 1 new chemical drug "LY03005" has been approved by the Center for Drug Evaluation of the State Drug Administration of China (CDE) approved a Phase III clinical trial for the treatment of generalized anxiety disorder .
-
Good news!
Time of Update: 2022-04-15
Cefdizazine sodium is a third-generation cephalosporin, which is mainly used clinically for pneumonia, bronchitis, pharyngitis, tonsillitis, pyelonephritis, urinary tract infection, and gonococcal urethritis caused by sensitive bacteria such as Streptococcus and pneumococcus.
-
PARP inhibitors - Can you see the hidden corners of the new anti-cancer trend?
Time of Update: 2022-03-10
Like all teenage heroes, when Olaparib first appeared and filled the global market expectations, the first Waterloo also arrived as scheduled in 2011: Phase II clinical results published in the New England Journal of Medicine in patients with platinum-sensitive ovarian cancer Among them, olaparib failed to prolong overall survival [3] .
-
Jingfeng Pharmaceutical's subsidiary flurbiprofen axetil injection obtained drug registration approval
Time of Update: 2022-03-10
On December 23, Jingfeng Pharmaceutical announced that its subsidiary, Pude Kangli, has obtained the drug registration approval for the chemical drug "flurbiprofen axetil injection" approved and issued by the State Food and Drug Administration .
Flurbiprofen axetil injection is a non-steroidal anti-inflammatory analgesic, clinically used for postoperative analgesia and cancer .
-
Importance of reverse screening for new drug discovery
Time of Update: 2022-03-10
However, this kind of so-called high-throughput screening is also relatively rough, and often occurs similar to the palladium-free catalyzed coupling reaction, which requires reverse screening to eliminate false positive hits .
-
Policy plus code!
Time of Update: 2022-03-10
The proportion of characteristic APIs with high technical barriers and high gross profit margins is relatively low, and the early domestic API industry chain advantages More concentrated on intermediates and some bulk APIs, and high value-added specialty APIs are more controlled by European, American and Indian companies .
-
Kintor's new crown drug Prokluamide US Phase III clinical trial failed to reach statistical significance
Time of Update: 2022-03-10
On the evening of December 27, the Hong Kong stock market of Kintor Pharmaceuticals issued an announcement announcing the progress of the Phase III clinical trial of proclutamide in the treatment of non-hospitalized patients with mild to moderate disease .
-
Ten billion varieties fell to the altar!
Time of Update: 2022-03-10
com China's public medical institutions terminal competition patternAmong the top 10 products, atorvastatin calcium tablets and rosuvastatin calcium tablets have long been the top brand products, and the cholesterol absorption inhibitor ezetimibe has risen from the tenth place in 2018 to the third place in the first half of 2021.
-
LINEPHARMA submits abortion drug license application in Japan
Time of Update: 2022-03-10
This drug is considered the international gold standard for medical abortion in early pregnancyi and is included in the World Health Organization (WHO) List of Essential Medicines for Abortion .
